Phase 2 Spinal Muscular Atrophy Trial, Recruiting NCT06169046 Sponsor: Gianni Soraru Condition: Spinal Muscular Atrophy
Back to Spinal Muscular Atrophy

Phase 2 Spinal Muscular Atrophy Trial, Recruiting

NCT06169046
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male and have been diagnosed with SBMA (Spinal and Bulbar Muscular Atrophy) confirmed by a genetic test showing a specific gene repeat number of 38 or higher
  • You are between 18 and 75 years old
  • You are experiencing one or more of the following: muscle wasting, weakness in your arms or legs, or difficulty with swallowing or speaking due to muscle weakness
  • You are able to walk on your own, even if you use a cane or another walking aid (but not a wheelchair)
  • You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

  • You have a diagnosed heart or cardiovascular condition that would make it unsafe for you to take a type of medication called beta2 agonists (the trial team will assess this)
  • You have certain other health conditions such as glaucoma, a severely enlarged prostate, an overactive thyroid, or a rare adrenal gland tumor, or another condition the trial team believes could put you at risk
  • You are currently taking beta-blocker medications or certain stimulant-type medications (note: if you take beta-blockers, you may still be eligible if you stop taking them at least 3 weeks before the trial starts — confirm with trial site)
  • You are unable to walk at all, or you can only walk with the physical support of another person
  • You have used beta2 agonist medications in the last 6 months
  • You have taken part in another clinical drug trial in the last 3 months
  • You have a muscle or nerve disease other than SBMA

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gianni Sorarù, MD, Azienda Ospedale Università di Padova

Phone: 0498213600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Gianni Soraru
Registry
ClinicalTrials.gov
Start date
13 April 2024
Est. completion
30 June 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

6-minute-walk test

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov